Divi's Labs Q2 result: Net profit rises 64% to ₹1,127 cr on higher revenue
Divi's Laboratories moved higher in a quarterly results development for FY27.
· BS Companies
Divi's Laboratories Ltd on Saturday posted a sharp 63.57 per cent rise in net profit to Rs 1,127 crore in the September quarter due to higher revenues. The company posted a net profit of Rs 689 crore in the corresponding period of the previous fiscal year, a regulatory filing said.
Key facts
- Period
- FY27
The analysis
Divi's Laboratories reported ₹1,127 cr, Rs 1,127 crore and Rs 689 crore for FY27, with movement of 64%, 63.57% and 35.39% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +1.8% on the day at ₹10,320.50, and has returned +23.6% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved +1.4% over the same period, so Divi's Laboratories is running 22.2 points ahead of its peers.
For Divi's Laboratories, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Divi's Laboratories (DIVISLAB), in Pharma & Healthcare.
- Over three months: Divi's Laboratories +23.6% against Pharma & Healthcare +1.4% (22.2 points ahead).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Divi's LaboratoriesDIVISLAB · Pharma & Healthcare | ₹10,320.50 | +1.8% | +8.1% | +23.6% | 0.0% | 1.3× | — |
Pharma & Healthcare
1M +3.0% · 3M +1.4%
Divi's Laboratories
Prices as of 6 Nov 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
ICICI Bank, Divi's among 14 NSE 500 stocks hit new highs in Muhurat session
Muhurat Trading 2026: Tata Steel, Sun Pharma, BSE among top gainers as Nifty 50, Sensex swing between gains and losses
Muhurat Trading 2026 Highlights | Closing Bell: Sensex ends Muhurat Trading marginally lower, Nifty below 25,000; Divi's Labs surges 7%
Muhurat Trading LIVE: GIFT Nifty signals muted open; Tata Steel, Divi's Labs shares in focus
Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore